These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18696011)

  • 1. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
    Schilling G; Bruweleit M; Harbeck N; Thomssen C; Becker K; Hoffmann R; Villena C; Schütte M; Hossfeld DK; Bokemeyer C; de Wit M
    Invest New Drugs; 2009 Apr; 27(2):166-72. PubMed ID: 18696011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
    Jahanzeb M; Mortimer JE; Yunus F; Irwin DH; Speyer J; Koletsky AJ; Klein P; Sabir T; Kronish L
    Oncologist; 2002; 7(5):410-7. PubMed ID: 12401903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
    Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
    Heinemann V; Di Gioia D; Vehling-Kaiser U; Harich HD; Heinrich B; Welt A; Ziske C; Deutsch G; Pihusch R; Kölbl H; Hegewisch-Becker S; Michl M; Stemmler HJ
    Ann Oncol; 2011 Mar; 22(3):603-608. PubMed ID: 20724574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
    Burstein HJ; Kuter I; Campos SM; Gelman RS; Tribou L; Parker LM; Manola J; Younger J; Matulonis U; Bunnell CA; Partridge AH; Richardson PG; Clarke K; Shulman LN; Winer EP
    J Clin Oncol; 2001 May; 19(10):2722-30. PubMed ID: 11352965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
    Papaldo P; Fabi A; Ferretti G; Mottolese M; Cianciulli AM; Di Cocco B; Pino MS; Carlini P; Di Cosimo S; Sacchi I; Sperduti I; Nardoni C; Cognetti F
    Ann Oncol; 2006 Apr; 17(4):630-6. PubMed ID: 16410363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
    Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
    Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Bayo-Calero JL; Mayordomo JI; Sánchez-Rovira P; Pérez-Carrión R; Illaramendi JJ; García-Bueno JM; González-Flores E; Crespo C; Ramos-Vázquez M; García-Palomo A; Ruiz-Borrego M; de la Haba J; Gómez-Bernal A; Yubero-Esteban A
    Clin Breast Cancer; 2008 Jun; 8(3):264-8. PubMed ID: 18650157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
    Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
    Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
    Morabito A; Longo R; Gattuso D; Carillio G; Massaccesi C; Mariani L; Bonginelli P; Amici S; De Sio L; Fanelli M; Torino F; Bonsignori M; Gasparini G
    Oncol Rep; 2006 Aug; 16(2):393-8. PubMed ID: 16820921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
    Tan WW; Allred JB; Salim M; Flynn P; Fishkin PA; Stella PJ; Wiesenfeld M; Bernath AM; Fitch TR; Perez EA
    Clin Breast Cancer; 2012 Apr; 12(2):81-6. PubMed ID: 22444716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.